ERBB2 and primitive neuroectodermal tumor: In a phase 1/2 clinical study, 19 HER2 positive subjects (16 OS, 1 EWS, one primitive neuroectodermal tumor, and one protofibroblastic small round cell tumor) were treated with HER2 CAR-T cells (Fig. 3).